Lead: A new Cochrane review published on Jan. 12, 2026, finds that structured physical activity can relieve depressive symptoms as effectively as pharmacological or psychological treatments in many cases. Researchers analyzed 73 randomized controlled trials involving roughly 5,000 people with depression, including participants who were also taking antidepressants. The evidence shows that even light-to-moderate activity — and combinations of aerobic and resistance training — produced measurable symptom relief within a few weeks of regular sessions.
Key Takeaways
- The review pooled 73 randomized controlled trials with about 5,000 participants and concluded exercise produced improvements comparable to medication or therapy in many studies.
- Benefits were seen with light-to-moderate activity; people who became slightly breathless during exercise saw gains early on.
- Combinations of aerobic and resistance training outperformed aerobic-only programs in the trials that compared modalities.
- The meta-analysis reported clinical improvement after roughly 13 to 36 exercise sessions, though long-term follow-up data were limited.
- Proposed mechanisms include increased neurotransmitter functioning (serotonin, dopamine, endorphins) and higher brain-derived neurotrophic factor (BDNF).
- Global clinical guidelines increasingly list exercise as a front-line or adjunctive treatment, but real-world implementation and adherence remain challenges.
- Exercise is low-cost with minimal side effects and can deliver mental, social and physical benefits when tailored to the individual.
Background
The Cochrane Collaboration, an independent international network that synthesizes randomized trial evidence, systematically reviewed trials testing exercise as a treatment for clinical depression. Trials spanned community and clinical settings and included participants who were treatment-naïve as well as those concurrently using antidepressants. Prior research has suggested mood benefits from physical activity, but this review aimed to compare exercise’s effect size directly with pharmacological and psychological interventions.
Depression is a leading cause of disability worldwide and a common reason patients seek primary care. Standard treatments include antidepressants and psychotherapies, but access, side effects and variable response rates leave many patients seeking alternatives or complements. Exercise has long been proposed as a scalable option, but clinicians have faced uncertainty about optimal dose, modality and how exercise compares with established treatments in randomized trials.
Main Event
Investigators pooled 73 randomized controlled trials involving roughly 5,000 adults diagnosed with depression. Across the analyzed studies, structured exercise programs—ranging from walking and jogging to mixed aerobic-and-resistance routines—were randomized against usual care, psychological therapy, pharmacotherapy or attention controls. The review found that, on average, exercise reduced depressive symptoms to a degree similar to medication or therapy in many trials included in the synthesis.
Authors and commentators emphasized the practical implications. Andrew Clegg, a professor at the University of Lancashire who contributed to the review, noted the similarity in effectiveness between exercise and other established treatments. Clinicians quoted in reporting highlighted that even modest increases in activity can produce clinically meaningful changes, particularly early in treatment when even low-dose activity may boost engagement and mood.
Mechanistic explanations reported alongside the review point to both neurochemical and neurotrophic effects. Clinicians described overlapping biochemical pathways with antidepressants—exercise can raise levels of serotonin, dopamine and endorphins—while also increasing neuroplasticity via factors such as BDNF. Trials that combined aerobic and strength training tended to show larger symptom reductions than aerobic-only programs in those head-to-head comparisons.
Despite favorable short-term outcomes, the reviewers and external experts flagged gaps: many trials were brief, and sustained long-term benefits, relapse prevention and adherence over months or years remain less well documented. Researchers also warned that quality and reporting of some trials varied, affecting certainty about subgroup effects and optimal prescriptions for different patient populations.
Analysis & Implications
The review’s conclusion that exercise can rival medication or therapy in symptom reduction reshapes how clinicians might present treatment options. For patients hesitant about medication or seeking complementary strategies, clinicians can now reliably discuss exercise as an evidence-based choice, not merely lifestyle advice. That said, equivalence in average effect size does not mean identical benefit for every individual; personalized care remains essential.
From a public-health perspective, exercise as a treatment offers advantages: low cost, broad accessibility and collateral benefits for physical health. Scaling exercise interventions—group programs, community prescriptions, structured clinician referrals—could reduce treatment gaps, but implementation requires resources for coaching, supervision and behavioral support to sustain adherence, especially for people with severe motivational deficits caused by depression.
Economically, increased use of exercise interventions could lower some medication- and therapy-related expenditures, but it also demands investment in delivery systems (trained facilitators, safe spaces, monitoring). Insurers and health systems that reimburse structured exercise programs or community-based initiatives may accelerate adoption and provide comparative data on long-term cost-effectiveness.
Comparison & Data
| Measure | Value (from review) |
|---|---|
| Randomized trials analyzed | 73 |
| Participants (approx.) | 5,000 |
| Sessions linked to improvement | 13–36 workouts |
| Effective intensities | Light to moderate (with gradual progression) |
| Modality with greater benefit | Aerobic + resistance training |
The table summarizes the core quantitative findings reported in the review. While short-term symptom reductions were consistently observed across studies, heterogeneity in trial designs—differences in diagnostic criteria, supervision levels, and comparator arms—limits precision about the single optimal “dose.” The reviewers note a need for larger, longer trials with standardized outcome measures to clarify durability and subgroup effects.
Reactions & Quotes
The review drew responses from clinicians who see exercise as a practical treatment option but emphasize implementation barriers. Below are representative statements with context.
“We found that exercise was as effective as pharmacological treatments or psychological therapies as well.”
Andrew Clegg, University of Lancashire
Clegg’s summary reflects the pooled comparisons in the review; he and coauthors caution that trial quality and follow-up length affect confidence in exact equivalence but say the overall signal supports exercise as a credible treatment pathway.
“This review reinforces the evidence that exercise is one of the most evidence-based tools for improving mood.”
Dr. Stephen Mateka, Medical Director of Psychiatry, Inspira Health
Mateka highlighted clinical utility: exercise can be an accessible option with minimal adverse effects. He and other clinicians note, however, that prescribing exercise requires time, behavioral support and systems-level changes for broad uptake.
“The brain in depression is thought to be less plastic…we know that exercise can also boost [BDNF].”
Dr. Nicholas Fabiano, University of Ottawa
Fabiano emphasized biological plausibility—exercise counters neuroplasticity deficits by increasing neurotrophic factors—supporting why activity can produce measurable clinical effects beyond mood alone.
Unconfirmed
- Whether exercise prevents new onset of major depressive episodes over the long term remains inadequately tested in large trials.
- Precise equivalence of exercise to medication for people with severe, recurrent, or treatment-resistant depression is not fully established.
- Optimal long-term dose, frequency and supervision level needed to sustain benefits across diverse populations require further confirmation.
Bottom Line
The Cochrane review strengthens the evidence that structured exercise is a legitimate, evidence-based treatment option for depression that often produces symptom improvements comparable to medication or psychotherapy in randomized trials. Even modest, light-to-moderate activity—especially when combining aerobic and resistance work—can yield meaningful reductions in depressive symptoms within several weeks.
For clinicians and policymakers, the priority now is translating these findings into practice: provide individualized exercise prescriptions, behavioral support to improve uptake and retention, and funding for programs that make activity safe and accessible. For patients, the findings mean that, alongside medication or therapy when appropriate, adopting regular movement—starting low and building up—can be a powerful component of recovery.
Sources
- NPR — Media report summarizing the Cochrane review and expert commentary (journalism)
- Cochrane Collaboration — Independent review organization; source of the systematic review methodology and pooled trial evidence (research organization)